ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 1286 • ACR Convergence 2020

    Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus by Physician Global Assessment of Disease Activity

    May Choi1, Emma Stevens2, Hongshu Guan2, Daniel Li3, Jack Ellrodt4, Benjamin Kargere4, Tianrun Cai2, Kazuki Yoshida5, Brendan Everett2 and Karen Costenbader6, 1Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 2Brigham and Women's Hospital, Boston, MA, 3Harvard, Columbus, OH, 4Williams College, Williamstown, 5Brigham & Women's Hospital and Harvard Medical School, Boston, MA, 6Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: The risk of cardiovascular disease (CVD), including myocardial infarction and stroke, is higher in SLE than in the general population. The excess risk of…
  • Abstract Number: 1302 • ACR Convergence 2020

    Exploration of Machine Learning Methods in Predicting Systemic Lupus Erythematosus Hospitalizations

    April Jorge1, Zhiyao Wu2, Tashrif Chowdhury2 and Yijun Zhao2, 1Massachusetts General Hospital, Boston, MA, 2Fordham University, Computer and Information Sciences Department, New York, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous disease associated with increased morbidity and mortality, and severe SLE flares can lead to hospitalizations. Our objective…
  • Abstract Number: 1512 • ACR Convergence 2020

    Trajectory Analysis of Repeat Renal Biopsies Identified Previous Endocapillary Proliferation as Predictor of Damage and End Stage Renal Disease in Pure Membranous Lupus Nephritis

    Andrea Fava1, Avi Rosenberg2, Serena Bagnasco2, Paride Fenaroli2, Jessica Li1, Jose Monroy-Trujillo2, Derek Fine2 and Michelle Petri3, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins University, Baltimore, 3Johns Hopkins University School of Medicine, Baltimore

    Background/Purpose: . Pure membranous (class V) lupus nephritis is considered a less aggressive phenotype, but renal fibrosis and chronic kidney disease may develop. Whether this…
  • Abstract Number: 1671 • ACR Convergence 2020

    Identifying Rare Genetic Variants in Childhood-onset Monogenic Systemic Lupus Erythematosus

    Melissa Misztal1, Fangming Liao2, Sergey Naumenko3, Andrea Knight4, Daniela Dominguez5, JingJing Cao2, Declan Webber6, Bhooma Thiruvahindrapuram7, Deborah Levy6, Andrew Paterson2, Earl D. Silverman8 and Linda Hiraki9, 1Genetics & Genome Biology, Research Institute, The Hospital for Sick Children, Oakville, ON, Canada, 2Genetics & Genome Biology, Research Institute, The Hospital for Sick Children, Toronto, Canada, 3The Centre for Computational Medicine, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada, 4Division of Rheumatology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 5Division of Rheumatology, The Hospital for Sick Children, Toronto, Canada, 6Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 7The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, 8Division of Rheumatology, The Hospital for Sick Children, Translational Medicine, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada, 9Division of Rheumatology, The Hospital for Sick Children, Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada

    Background/Purpose: Among children diagnosed with systemic lupus erythematosus (SLE), there exists monogenic forms of SLE, where rare variants in a single gene lead to disease.…
  • Abstract Number: 1773 • ACR Convergence 2020

    Worse Maternal and Fetal Outcomes Among Hospitalized U.S. Pregnant Women with Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA)

    Christine Anastasiou1, Laura Trupin1, Patricia Katz2, Zara Izadi3, Milena Gianfrancesco1, Gabriela Schmajuk4 and Jinoos Yazdany5, 1University of California, San Francisco, San Francisco, CA, 2University of California, San Francisco, Novato, CA, 3University of California San Francisco, San Francisco, CA, 4University of California, San Francisco, Atherton, CA, 5UCSF, San Francisco, CA

    Background/Purpose: Prior studies suggest women with SLE and RA may have higher age-adjusted risk of adverse pregnancy outcomes. We evaluated maternal and fetal complications and…
  • Abstract Number: 1800 • ACR Convergence 2020

    Association of Air Pollution with Systemic Lupus Erythematosus Disease Activity in the Central Valley of California

    Mosaab Mohameden1, Ali H.Ali2, Zi Ying Li2, Yabsira Abejie3, Ratnali Jain2 and Candice Reyes Yuvienco4, 1University of Cincinnati College of Medicine, Cincinnati, OH, 2University of California San Francisco Fresno, Fresno, CA, 3Floyd B. Buchanan High School, Fresno, CA, 4University of California San Francisco Fresno, Clovis, CA

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex multisystem autoimmune disease that affects at least 300,000 people in the United States creating a substantial socioeconomic…
  • Abstract Number: 1818 • ACR Convergence 2020

    IgG and IgA Autoantibodies Against L1 ORF1p Expressed in Granulocytes Correlate with Granulocyte Consumption and Disease Activity in Pediatric Systemic Lupus Erythematosus

    Kennedy Ukadike1, Kathryn Ni1, Victoria Carter1, Martin Taylor2, John LaCava3, Lauren Pachman4, Xiaoxing Wang1, Mary Eckert5, Anne Stevens1, Christian Lood1 and Tomas Mustelin1, 1University of Washington, Seattle, WA, 2Massachusetts General Hospital, Boston, MA, 3Rockefeller University, New York, NY, 4Department of Pediatrics, Northwestern University Feinberg School of Medicine; The Ann and Robert H. Lurie Children's Hospital of Chicago, Division of Pediatric Rheumatology; The CureJM Center of Excellence in Juvenile Myositis Research and Care, The Stanley Manne Children's Research Center of Chicago, Lake Forest, IL, 5Seattle Children's Hospital, Seattle, WA

    Background/Purpose: To quantitate autoantibodies against the RNA-binding p40 (ORF1p) protein encoded by the L1 retroelement, expression of p40 itself, and markers of neutrophil death in…
  • Abstract Number: 1834 • ACR Convergence 2020

    Biomarker Analysis of IFN-I Modulation in JNJ-839: First-in-Human Study for Systemic Lupus Erythematosus

    Ashley Orillion1, Loqmane Seridi1, Matteo Cesaroni2, Jessica Schreiter1, Jacqueline Benson3, William Stohl4, Walter Winn Chatham5, Richard Alan Furie6, Thi-Sau Migone7, Stanley Marciniak1, Zhenling Yao1, Bhaskar Srivastava1, Marc Chevrier2 and Jarrat Jordan1, 1Janssen Research & Development, LLC, Spring House, PA, 2Janssen Research & Development, LLC, Spring House, 3Janssen Research & Development, LLC, South San Francisco, CA, 4University of Southern California Keck School of Medicine, Los Angeles, CA, 5University of Alabama at Birmingham, Birmingham, AL, 6Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, 7Independent Consultant, Spring House

    Background/Purpose: JNJ-839 is a fully human neutralizing antibody selective to human IFN-ω and IFN-α subtypes. Here we report the exploratory biomarker analyses of a Phase…
  • Abstract Number: 1986 • ACR Convergence 2020

    Determinants of Variation in Pediatric Systemic Lupus Erythematosus Care Delivery

    Jon Burnham1, Rosemary Peterson1, Joy Ukaigwe1, Lynsey Cecere1, Andrea Knight2 and Joyce Chang1, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2Division of Rheumatology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Patients with pediatric systemic lupus erythematosus (pSLE) receive only a fraction of recommended care.  Moreover, variation in care delivery likely contributes to pervasive racial…
  • Abstract Number: 0045 • ACR Convergence 2020

    Healthcare Practitioner Confidence Assessing Rashes in Patients of Skin of Color with Lupus

    Vijay Kannuthurai1, Jacob Murray2, Lisa Zickuhr3 and Ling Chen2, 1Washington University in St. Louis School of Medicine, Hazlehurst, MS, 2Washington University in St. Louis School of Medicine, St. Louis, MO, 3Washington University/B-JH/SLCH Consortium, St. Louis, MO

    Background/Purpose: Medical education can promote bias that disproportionately affects patients of color. Patients of color with lupus are especially vulnerable as they often carry a…
  • Abstract Number: 0255 • ACR Convergence 2020

    Effect of Removing Haemolytic and Gastrointestinal Activity from the Operational Definition of the Lupus Low Disease Activity State – Implications for Use as a Trial Endpoint

    Vera Golder1, Rangi Kandane-Rathnayake1, Molla Huq2, Worawit Louthrenoo3, Shue Fen Luo4, Yeong-Jian Wu5, Aisha Lateef6, Sargunan Sockalingam7, Sandra Navarra8, Leonid Zamora9, Laniyati Hamijoyo10, Yasuhiro Katsumata11, Masayoshi Harigai12, Madelynn Chan13, Sean O'Neill14, Fiona Goldblatt15, Chak Sing Lau16, Zhanguo Li17, Alberta Hoi18, Mandana Nikpour19 and Eric Morand20, 1Monash University, Clayton, Victoria, Australia, 2University of Melbourne, Melbourne, Victoria, Australia, 3Maharaj Nakorn Chiangmai, Muang, Thailand, 4Chang Gung Memorial Hospital-Linkou, Taoyuan, Taipei, Taiwan (Republic of China), 5Chang Gung Memorial Hospital, Guishan, Taiwan (Republic of China), 6National University Hospital, Singapore, Singapore, 7University of Malaya, Kuala Lumpur, Malaysia, 8University of Santo Tomas, Manila, Philippines, 9University of Santo Thomas, Manila, Philippines, 10University of Padjadjaran, Bandung, Indonesia, 11Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 12Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, 13Tan Tock Seng Hospital, Singapore, Singapore, 14Sydney University, Sydney, Australia, 15Royal Adelaide Hospital, Adelaide, Australia, 16Hong Kong University, Hong Kong, Hong Kong, 17Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China (People's Republic), 18Monash University, Melbourne, Victoria, Australia, 19The University of Melbourne at St. Vincent's Hospital, Melbourne, Victoria, Australia, 20Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia

    Background/Purpose: The Lupus Low Disease Activity State (LLDAS) has recently undergone prospective longitudinal validation in a multinational cohort, demonstrating the association of attaining LLDAS with…
  • Abstract Number: 0272 • ACR Convergence 2020

    Superior Discrimination Between LLDAS and DORIS Remission with Modification of Prednisolone Dose Threshold

    Eric Morand1, Vera Golder2, Worawit Louthrenoo3, Shue Fen Luo4, Yeong-Jian Wu5, Aisha Lateef6, Sargunan Sockalingam7, Sandra Navarra8, Leonid Zamora9, Laniyati Hamijoyo10, Yasuhiro Katsumata11, Masayoshi Harigai12, Madelynn Chan13, Sean O'Neill14, Fiona Goldblatt15, Yi-Hsing Chen16, Yanjie Hao17, Zhuoli Zhang17, Jun Kikuchi18, Tsutomu Takeuchi19, Chak Sing Lau20, Zhanguo Li21, Alberta Hoi22, Mandana Nikpour23 and Rangi Kandane-Rathnayake2, 1Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, 2Monash University, Clayton, Victoria, Australia, 3Chiang Mai University Hospital, Muang, Thailand, 4Chang Gung Memorial Hospital-Linkou, Taoyuan, Taipei, Taiwan (Republic of China), 5Chang Gung Memorial Hospital, Guishan, Taiwan (Republic of China), 6National University Hospital, Singapore, Singapore, 7University of Malaya, Kuala Lumpur, Malaysia, 8University of Santo Tomas, Manila, Philippines, 9University of Santo Thomas, Manila, Philippines, 10University of Padjadjaran, Bandung, Indonesia, 11Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 12Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, 13Tan Tock Seng Hospital, Singapore, Singapore, 14Sydney University, Sydney, Australia, 15Royal Adelaide Hospital, Adelaide, Australia, 16Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), 17Peking University First Hospital, Beijing, China (People's Republic), 18Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 19Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, 20Hong Kong University, Hong Kong, Hong Kong, 21Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China (People's Republic), 22Monash University, Melbourne, Victoria, Australia, 23The University of Melbourne at St. Vincent's Hospital, Melbourne, Victoria, Australia

    Background/Purpose: Treat-to-target (T2T) approaches to rheumatic disease require the definition and validation of low disease activity and remission endpoints that should be concentrically more stringent.…
  • Abstract Number: 0290 • ACR Convergence 2020

    Role of Protein Tyrosine Phosphatase 1B (PTP1B) in Endothelial-to-Mesenchymal Transition (EndoMT) Promoted by Inflammation: Implications for SLE

    Jorge Romo-Tena1, José Esparza-López2, Carmelo Carmona-Rivera3, Luz Blanco4, Mariana Kaplan3 and María de Jesús Ibarra-Sánchez2, 1NIAMS, National Institute of Health, Bethesda, 2INNSZ / UNAM-RAI, Mexico City, Mexico, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, Centreville

    Background/Purpose: The endothelial-to-mesenchymal transition (EndoMT) transdifferentiation process can be promoted by several proinflammatory mediators in many pathological conditions. Recently, it was suggested a crucial role…
  • Abstract Number: 0431 • ACR Convergence 2020

    Hydroxychloroquine Use Was Not Associated with QTc Length in a Large Cohort of SLE and RA Patients

    Elizabeth Park1, Jon Giles2, Thania Perez-Recio1, Paloma Pina3, Christopher Depender1, Joan Bathon1 and Laura Geraldino-Pardilla4, 1Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, 2Columbia University, New York, NY, 3Cardiac Electrophysiology, Northwestern Medicine, Chicago, IL, 4Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York

    Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone therapy for systemic lupus erythematosus (SLE), and is used as monotherapy and combined with other DMARDs in rheumatoid arthritis…
  • Abstract Number: 0529 • ACR Convergence 2020

    A Prospective Study on the Incidence of a First Thrombo-embolic Event in Patients with Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies

    Savino Sciascia1, Massimo Radin1, Irene Cecchi1, Daniela Rossi1 and Dario Roccatello2, 1University of Torino, Torino, Italy, 2S Giovanni Hospital, Univ of Turin, Turin, Italy

    Background/Purpose: Prospective data confirming the role of anti-phosphatidylserine/prothrombin antibodies (aPS/PT) in the absence of other aPL tested by β2–glycoprotein I-depend assays are missing.Methods: Since 2015 aPSPT…
  • « Previous Page
  • 1
  • …
  • 120
  • 121
  • 122
  • 123
  • 124
  • …
  • 150
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology